This is a phase I trial of nimotuzumab that will be conducted in patients with advanced
incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and
recommended phase II doses of nimotuzumab that can be safely given to patients with advanced
and/or metastatic solid tumors.